Document:

Exhibit 10.2 Resolutions Regarding Non-Employee Lead Director Fee Allcorp 3.31.15

EXHIBIT 10.2 

RESOLUTION

Lead Director Fee

RESOLVED, that effective May 19, 2015, that any director who serves as Lead Director shall be entitled to receive an additional quarterly fee in the amount of $12,500 (“Quarterly Lead Director Fee”), to be paid on each January 1, April 1, July 1, and October 1, (each a “Quarterly Payment Date”), provided such director is serving as Lead Director on such date. 

FURTHER RESOLVED, that any director initially elected by the Board as Lead Director effective on any date other than a Quarterly Payment Date, shall be entitled to receive on the Quarterly Payment Date following the date he or she becomes Lead Director, an additional one-time fee in an amount equal to the Quarterly Lead Director Fee, multiplied by a fraction, the numerator of which is the number of calendar days such director has served as Lead Director prior to such Quarterly Payment Date and the denominator of which is 91.Ex 10.57 Revised Trustee Comp Plan

Exhibit 10.57
TRUSTEE COMPENSATION SUMMARY
(effective January 1, 2015)

Annual Retainers
Our non-employee trustees (other than our Chairman) will receive an annual retainer of $35,000 plus $1,500 per committee meeting. Our Chairman will receive an annual retainer of $110,000, with no additional compensation for committee meetings attended. Our Chairman does not sit on any of our committees, but routinely attends committee meetings in the course of exercising his duties as Chairman. 

Committee Chair Additional Retainers
Our Committee Chairs will receive additional retainers as follows: Audit Committee, $15,000; Corporate Governance/Nominating Committee, $11,000; and Compensation Committee, $11,000.  Audit Committee members were also paid an additional retainer of $3,750. 

Annual Equity Grant
Our non-employee trustees will receive an annual $100,000 common share grant, awarded (a) 50% on the earlier of the annual shareholder meeting date or May 15, and (b) the remaining 50% on December 15.  The number of common shares is determined by the closing price of the common shares on the date of grant. These common shares vest immediately but are restricted in transfer so long as the trustee serves on the Board. 

DCP
Washington REIT has adopted a non-qualified deferred compensation plan for non-employee trustees which was amended and restated effective October 22, 2013. The plan allows any non-employee trustee to defer a percentage or dollar amount of his or her cash compensation and/or all of his or her share compensation. Cash compensation deferred is credited with interest equivalent to the weighted average interest rate on Washington REIT's fixed rate bonds as of December 31 of each calendar year. The non-employee trustee may alternatively elect to designate that all of his or her annual board retainer and/or all of his or her share compensation be converted into restricted share units at the market price of common shares as of the end of the applicable quarter. The restricted share units are credited with an amount equal to the corresponding dividends paid on Washington REIT's common shares. Upon the expiration of a trustee's service, the deferred compensation plus earnings can be paid in either a lump sum or, in the case of deferred cash compensation only, in installments pursuant to a prior election of the trustee.  Compensation deferred into restricted share units is paid in the form of shares.  Upon a trustee's death, the trustee's beneficiary will receive a lump sum pay out. The plan is unfunded and payments are to be made from general assets of Washington REIT.Ex 10.58 Amendment to STIP and LTIP

Exhibit 10.58
Statement of Amendment
of STIP and LTIP for S. Riffee
On March 4, 2015, the Board of Trustees and Compensation Committee of Washington Real Estate Investment Trust (the “Trust”) adopted the following amendments to the Short-term Incentive Plan, effective January 1, 2014 (the “STIP”) and the Long-term Incentive Plan, effective January 1, 2014 (the “LTIP”).
STIP Amendment
The following threshold, target and high Award opportunity levels shall apply under the STIP with respect to Stephen E. Riffee (to be used with respect to Mr. Riffee only in lieu of the Award opportunity levels in Section 4.1 of the STIP):
	
								
	 
	Cash Component (50%)
	 
	Restricted Share Component (50%)

	 
	Threshold
	Target
	High
	 
	Threshold
	Target
	High

	Stephen E. Riffee as Executive Vice President and Chief Financial Officer
	42%
	87.5%
	140%
	 
	42%
	87.5%
	140%

LTIP Amendment
The following threshold, target and high Award opportunity levels shall apply under the LTIP with respect to Mr. Riffee (to be used with respect to Mr. Riffee only in lieu of the Award opportunity levels in Section 4.1 of the LTIP):
	
				
	 
	Threshold
	Target
	High

	Stephen E. Riffee as Executive Vice President and Chief Financial Officer
	44%
	95%
	149%

This Statement of Amendment is made as of March 4, 2015 to serve as the written memorialization of such STIP and LTIP amendments.
	
			
	WASHINGTON REAL ESTATE INVESTMENT TRUST

	 
	 
	 

	 
	 
	 

	 
	 
	 

	By:
	/s/ Laura M. Franklin
	 

	 
	Laura M. Franklin
	 

	 
	Executive Vice President - Accounting and AdministrationExh 10.1 Ipsen Agreement

Confidential materials omitted and filed separately
with the Securities and Exchange Commission.
Asterisks denote omissions.

Exhibit 10.1

FIRST AMENDMENT
TO LICENSE AND COLLABORATION AGREEMENT

This First Amendment to License and Collaboration Agreement (the “Amendment”) is entered into effective as of the last date set forth on the signature page hereof (the “Amendment Effective Date”) by and between LEXICON PHARMACEUTICALS, INC., a Delaware corporation with its principal offices at 8800 Technology Forest Place, The Woodlands, Texas 77381 U.S.A. (“Lexicon”), and IPSEN PHARMA SAS, a French corporation with its principal offices at 65 Quai Georges Gorse, Boulogne-Billancourt 92100, France (“Ipsen”).

Capitalized terms not otherwise defined herein shall have the meaning given to such terms in the Collaboration Agreement.  Unless otherwise expressly stated herein, the Sections referred to herein refer to the Sections in the Collaboration Agreement.

R E C I T A L S

WHEREAS, Lexicon and Ipsen are parties to that certain License and Collaboration Agreement dated October 21, 2014 (the “Collaboration Agreement”);

WHEREAS, Lexicon and Ipsen desire to amend the Collaboration Agreement to include Canada in the Licensed Territory and reflect additional financial provisions relating thereto.

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, Lexicon and Ipsen hereby agree as follows:

1.    In consideration of the expanded license rights granted by Lexicon to Ipsen by virtue of this Amendment, Ipsen shall pay Lexicon a one-time, non-refundable, non-creditable milestone payment of [**] Dollars (US$[**]) within fifteen (15) days after the Amendment Effective Date.

2.    Section 1.40 of the Collaboration Agreement is hereby amended and restated in its entirety as follows: 

“Section 1.40    “Lexicon Territory” means the USA and Japan.”

3.    Section 4.1(c) of the Collaboration Agreement is hereby amended and restated in its entirety as follows:

“(c)    Ipsen shall pay Lexicon, within [**] following [**], for (i) all internal costs of Lexicon personnel at the FTE Rate, plus (ii) all out-of-pocket costs and expenses incurred by Lexicon, with respect to each of clause (i) and (ii) to the extent incurred in transferring to Ipsen Regulatory Approvals and regulatory filings (or providing Ipsen with a right of reference thereto), providing copies of Regulatory Approvals and regulatory filings, Regulatory Documentation, and the Drug Master File, and performing other regulatory activities assigned to Lexicon under the Development Plan or Commercialization Plan, provided that (x) such costs shall be appropriately apportioned to the extent they are also related to activities for countries outside the Licensed Territory (e.g. USA and/or Japan), and (y) all the foregoing is in accordance with the costs and expenses forecasted in the applicable budget as approved by the JSC or is additionally requested by Ipsen, it being understood that such approved budget shall include an allowance of [**] percent ([**]%) for cost overruns, provided such overruns, upon their occurrence, are appropriately documented and justified, and that Lexicon’s obligations to perform activities pursuant to Sections 4.1(a) and 4.1(b) shall be subject to prior approval by the JSC of a budget therefor.”

Confidential materials omitted and filed separately
with the Securities and Exchange Commission.
Asterisks denote omissions.

4.    Section 8.2(a) of the Collaboration Agreement is hereby amended and restated in its entirety as follows: 

“(a)    Ipsen shall pay Lexicon the following event milestone payments, subject to adjustment pursuant to Section 8.2(b) and (c):
	
			
	Milestone Event 
	U.S. Dollars
(in Millions)

	 
	 
	 

	(i)
	[**]
	U.S.$[**]

	 
	 
	 

	(ii)
	[**]
	U.S.$[**]

	 
	 
	 

	(iii)
	[**]
	U.S.$[**]

	 
	 
	 

	(iv)
	[**]
	U.S.$[**]

	 
	 
	 

	(v)
	[**]
	U.S.$[**]

	 
	 
	 

	(vi)
	[**]
	U.S.$[**]

	 
	 
	 

	(vii)
	[**]
	U.S.$[**]

	 
	 
	 

	(viii)
	[**]
	U.S.$[**]

	 
	 
	 

	(ix)
	[**]
	U.S.$[**]

	 
	 
	 

	(x)
	[**]
	U.S.$[**]”

	 
	 
	 

5.    For purposes of this Amendment, “Health Canada” shall mean Health Canada, the federal department of the government of Canada having the authority to regulate the sale of medicinal or pharmaceutical products, or any successor agency thereof.

6.    This Amendment shall not amend or modify the covenants, terms, conditions, rights and obligations of the parties under the Collaboration Agreement, except as specifically set forth herein.  The Collaboration Agreement shall continue in full force and effect in accordance with its terms as amended by this Amendment.
7.    This Amendment may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

Confidential materials omitted and filed separately
with the Securities and Exchange Commission.
Asterisks denote omissions.

IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute and deliver this Amendment as of the Amendment Effective Date.

IPSEN PHARMA SAS

By:                         
(Signature of Authorized Representative)

Printed Name:                     

Title:                         

Date:                         

LEXICON PHARMACEUTICALS, INC.

By:                         
(Signature of Authorized Representative)

Printed Name:                     

Title:                         

Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]